BioSpace News Archive

Isofol Medical AB, announced that the company invites investors, analysts, and media to a live-streamed R&D Event with a subsequent question and answer session on June 20 at 12:30 CEST.

Hyperfine, Inc., creator of the Swoop® Portable MR Imaging System™, the world’s first US FDA-cleared portable magnetic resonance imaging device, announced that it has completed registration and notification of the device in Australia and New Zealand.

Spirea Limited, a Cambridge company created to advance a new generation of antibody drug conjugate therapeutics, has announced that it has secured funding of £2.4 million with investments from high-profile UK and US investors.

I-VASC, the Italy based start-up company which has developed and CE Marked its innovative percutaneous VELEX™ system to treat CVI, a condition that includes varicose veins disease, announces that VELEX™ has entered clinical use, with the first two cases performed last week in Milan at the Policlinico San Donato center, the renowned institution of medical science.

MolecuLight Corp., the leader in point-of-care fluorescence imaging for the real-time detection of bacteria in wounds, announces it has been awarded a new group purchasing agreement with Premier, Inc.

The Company will offer Ventis Pharma’s patented local anesthetic compound, Endura-Kit TM for post-operative surgical and chronic pain management.

Clover Biopharmaceuticals, Ltd. announced that the first patient has been dosed with SCB-219M, an innovative thrombopoietin receptor agonist mimetic Fc-fusion protein, in a Phase 1 clinical trial to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and efficacy of SCB-219M in cancer patients with chemotherapy-induced thrombocytopenia.

Clearside Biomedical, Inc. today announced the appointment of Susan L. Coultas, Ph.D., as Chief Clinical Officer.

Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a publication in Expert Review of Neurotherapeutics titled “ A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain” by Eugene R. Viscusi, M.D.

Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal year ended March 31, 2022.